| Fereshteh Boozarjomehri, MD | |
|
190 Welles St Ste 112-114, Kingston, PA 18704-4968 | |
| (570) 714-1099 | |
| (570) 714-1116 |
| Full Name | Fereshteh Boozarjomehri |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 43 Years |
| Location | 190 Welles St Ste 112-114, Kingston, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083689921 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger-community Medical Center | Scranton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
Essilor today announced the launch of Optifog, the first high-performance anti-fogging lenses, in response to high consumer demand. This new category of lenses represents a major technological breakthrough in keeping with the long tradition of innovation at Essilor.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.
› Verified 6 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Essilor today announced the launch of Optifog, the first high-performance anti-fogging lenses, in response to high consumer demand. This new category of lenses represents a major technological breakthrough in keeping with the long tradition of innovation at Essilor.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fereshteh Boozarjomehri, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Fereshteh Boozarjomehri, MD 190 Welles St Ste 112-114, Kingston, PA 18704-4968 Ph: (570) 714-1099 |
News Archive
Essilor today announced the launch of Optifog, the first high-performance anti-fogging lenses, in response to high consumer demand. This new category of lenses represents a major technological breakthrough in keeping with the long tradition of innovation at Essilor.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.
Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.
› Verified 6 days ago
Dr. Michael Miller, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 676 Wyoming Ave, Suite 104, Kingston, PA 18704 Phone: 570-287-1400 | |
Dr. Bonita M Mancia, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 440 Pierce St, Kingston, PA 18704 Phone: 570-288-6521 Fax: 570-288-8284 | |
Mark S Polin, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 445 Wyoming Ave, Kingston, PA 18704 Phone: 570-714-2300 | |
Michael Joseph Paglia, MD, PHD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 190 Welles St, Kingston, PA 18704 Phone: 570-714-1099 Fax: 570-714-1116 | |
Dr. George C. Tsoutsoplides, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 534 Wyoming Avenue, Kingston, PA 18704 Phone: 570-287-5900 Fax: 570-287-6610 |